RxDoctor Payments Data

Tabitha Oravetz

Nurse Practitioner · Jacksonville, FLNPI 1497164768

Payments from drug & device makers

$14,263in general payments, 2019–2025

Across 809 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Sanofi-aventis U.S. LLC$969
  • Lilly USA, LLC$950
  • Abbott$935
  • Mannkind Corporation$914
  • AstraZeneca$892
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$14,206100%
  • Education$570%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,263 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$90,746
Medicare patients
433
Services billed
2,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide252$457,569
MounjaroTirzepatide229$301,408
JardianceEmpagliflozin113$162,844
Synjardy XrEmpagliflozin/Metformin Hcl56$85,113
TrulicityDulaglutide45$78,428
Tresiba Flextouch U-100Insulin Degludec95$77,255
FarxigaDapagliflozin Propanediol76$65,564
Tresiba Flextouch U-200Insulin Degludec43$65,509
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog44$61,866
Humalog Kwikpen U-200Insulin Lispro21$44,243
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$42,503
Xigduo XrDapaglifloz Propaned/Metformin27$42,438
JanuviaSitagliptin Phosphate29$41,940
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog56$37,199
ProliaDenosumab20$35,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,834$485,046278 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$950$391,739316 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$432$262,965185 claims
AstraZenecaFarxiga$892$65,56476 claims
MerckJanuvia$212$41,94029 claims
AmgenProlia$877$35,29320 claims
AbbVieSynthroid, Armour Thyroid$229$12,930125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →